Johnson & Johnson has released groundbreaking clinical trial results for Erda-iDRS (formerly TAR-210), an investigational intravesical drug-delivering system designed to treat FGFR-altered non-muscle-invasive bladder cancer. The company announced the data during a late-breaking oral session at the European Association of Urology (EAU) 2026 Annual Meeting in London, marking a significant milestone in precision oncology for early-stage bladder cancer.
The Phase 1 trial results demonstrate the potential of Erda-iDRS to become the first targeted treatment for early-stage bladder cancer, offering a new hope for patients with intermediate-risk disease who often face frequent recurrences and multiple surgical procedures.
Erda-iDRS Bladder Cancer Treatment: Phase 1 Clinical Trial Results
The open-label, multicenter Phase 1 study evaluated Erda-iDRS in patients with intermediate-risk and high-risk non-muscle-invasive bladder cancer (NMIBC) whose tumors contain specific fibroblast growth factor receptor (FGFR) alterations. The trial met its primary safety endpoint while demonstrating remarkable efficacy outcomes.
Intermediate-Risk NMIBC Cohort Results
- Complete response rate: 89% (95% confidence interval, 78-95) following tumor assessment during the initial treatment period.
- Median duration: 18 months (95% CI, 14-25) of complete response.
- Follow-up range: 15 to 21 months, with 49% of patients remaining in active follow-up.
- Patient population: 62 patients with recurrent intermediate-risk NMIBC as of November 3, 2025.
High-Risk NMIBC Cohort Results
- Median recurrence-free survival: 20 months (95% CI, 15-30).
- 12-month recurrence-free survival rate: 83% (95% CI, 62-93).
- Follow-up duration: 24 months with 31% of patients remaining in active follow-up.
- Patient population: 26 patients with recurrent, BCG-experienced high-risk NMIBC.
These results represent a substantial advancement over current standard-of-care treatments for this patient population, demonstrating the efficacy of targeted FGFR inhibition in early-stage bladder cancer.
Read More: Johnson & Johnson’s Imaavy Wins European Commission Approval for Generalized Myasthenia Gravis
Safety Profile and Tolerability
Erda-iDRS demonstrated a favorable and manageable safety profile across both cohorts, with predominantly localized adverse events:
- No dose-limiting toxicities observed during the trial.
- Most common treatment-related adverse events (TRAEs): hematuria (32%) and dysuria (22%), both localized bladder effects.
- Grade 3+ TRAEs: Occurred in only 4 patients (5%).
- Treatment discontinuation: 8 patients (9%) discontinued due to adverse events.
- Serious TRAEs: 2 patients (2%) experienced serious treatment-related adverse events.
- Systemic exposure: Limited systemic exposure with no observed hyperphosphatemia.
he localized safety profile is particularly significant because it reflects Erda-iDRS’s unique mechanism of action delivering the therapeutic agent directly to the bladder through intravesical administration while minimizing systemic exposure to the drug.
Understanding FGFR Alterations in Bladder Cancer
FGFR (fibroblast growth factor receptor) alterations are commonly found in early-stage bladder cancer, occurring in approximately:
- 70% of intermediate-risk non-muscle-invasive bladder cancer tumors.
- 40% of high-risk non-muscle-invasive bladder cancer tumors.
These genetic changes are significant because they often drive tumor growth and proliferation. Erdafitinib is an oral kinase inhibitor that specifically targets and blocks FGFR signaling, thereby halting the growth-promoting pathways in FGFR-altered cancers. However, oral erdafitinib can cause systemic side effects due to widespread drug distribution throughout the body.
Erda-iDRS represents an innovative solution to this challenge by delivering erdafitinib directly into the bladder through an intravesical drug-releasing system that provides prolonged release over a three-month period. This localized delivery approach enables high therapeutic concentrations at the disease site while minimizing systemic drug exposure and associated adverse effects.
Clinical Significance and Unmet Medical Need
Non-muscle-invasive bladder cancer accounts for approximately 75% of newly diagnosed bladder cancer cases and is categorized as low-, intermediate-, or high-risk based on tumor characteristics and recurrence likelihood.
Intermediate-Risk Disease Challenges
- Characterized by frequent tumor recurrences.
- Patients often require multiple TURBT procedures (transurethral resection of bladder tumors).
- Ongoing surveillance and monitoring obligations.
- Risk of disease progression to the muscle-invasive stage.
- Lack of targeted, precision-based approaches in current treatment.
High-Risk Disease Challenges
- Substantially higher likelihood of progression to muscle-invasive disease.
- Many patients develop BCG-unresponsive disease, limiting treatment options.
- May ultimately require radical cystectomy (complete bladder removal).
- Significant impact on patient quality of life and morbidity.
- High recurrence and progression rates despite current therapy.
For patients with FGFR-altered non-muscle-invasive bladder cancer, care has historically not been guided by precision-based approaches. The high and durable complete responses demonstrated with Erda-iDRS highlight the opportunity to deliver a targeted therapy to these patients. Bringing a biology-based approach into earlier stages of this disease has the potential to change how these patients are treated.
Dr. Christopher Cutie, Vice President, Disease Area Leader, Bladder Cancer, Johnson & Johnson
How Erda-iDRS Works: Innovation in Drug Delivery
Erda-iDRS represents a significant innovation in drug delivery technology for cancer treatment. The system is designed as an intravesical drug-releasing system that delivers prolonged, localized erdafitinib directly to the bladder:
- Localized delivery: Concentrates the drug directly at the tumor site within the bladder.
- Prolonged release: Provides consistent drug delivery over a three-month period.
- Reduced systemic exposure: Minimizes the amount of drug that enters the bloodstream.
- Improved tolerability: Enables effective treatment with fewer systemic side effects.
- Patient convenience: Three-month treatment cycles reduce procedure frequency compared to .weekly BCG therapy.
Future Development: The MoonRISe Program
Based on the promising Phase 1 results, Johnson & Johnson has launched the MoonRISe program—a comprehensive clinical development initiative designed to further evaluate Erda-iDRS across different disease stages and patient populations. The program includes three major clinical trials:
MoonRISe-1: Adjuvant Treatment for Intermediate-Risk NMIBC
- Trial Type: Phase 3 randomized controlled study (NCT06319820).
- Population: Patients with intermediate-risk NMIBC.
- Setting: Adjuvant setting (after tumor resection).
- Objective: Compare Erda-iDRS against single-agent intravesical cancer treatment.
MoonRISe-2: Ablative Treatment for Intermediate-Risk NMIBC
- Trial Type: Phase 2 study (NCT05316155).
- Population: Patients with intermediate-risk NMIBC with visible tumors.
- Setting: Ablative setting (treating visible tumors without surgery).
- Objective: Evaluate efficacy and safety of non-surgical tumor treatment.
MoonRISe-3: Treatment for High-Risk NMIBC with Prior BCG
- Trial Type: Phase 3 randomized controlled study (NCT06919965).
- Population: Patients with high-risk papillary NMIBC who received prior BCG therapy.
- Inclusion: BCG-unresponsive disease patients who have limited treatment options.
- Setting: Adjuvant setting (after tumor resection).
- Objective: Compare Erda-iDRS against intravesical chemotherapy.
These Phase 2 and Phase 3 trials represent a comprehensive clinical development strategy that addresses multiple patient populations and disease stages, building on the success demonstrated in the Phase 1 trial.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
The Broader Significance for Precision Oncology
This announcement reflects the broader shift in oncology toward precision medicine—treatment approaches guided by the specific genetic and molecular characteristics of individual tumors. Rather than using one-size-fits-all chemotherapy or BCG immunotherapy, Erda-iDRS offers targeted treatment specifically for patients whose cancers are driven by FGFR alterations.
The clinical trial methodology employed genetic testing (urine and/or tissue testing) to identify FGFR alterations, ensuring patients received a therapy specifically targeting their molecular disease driver. This precision-based approach enhances efficacy while minimizing unnecessary exposure to patients unlikely to benefit.
Johnson & Johnson’s development of Erda-iDRS also demonstrates the value of innovative drug delivery systems in expanding therapeutic options. By reformulating an existing drug (erdafitinib) as a localized intravesical delivery system rather than oral administration, the company has addressed key limitations of the oral formulation while potentially enabling treatment of earlier disease stages.
Last Modified:
